The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera

Abstract To assess the impact of the key non-synonymous amino acid substitutions in the RBD of the spike protein of SARS-CoV-2 variant B.1.617.1 (dominant variant identified in the current India outbreak) on the infectivity and neutralization activities of the immune sera, L452R and E484Q (L452R-E48...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Precision clinical medicine 2021-09, Vol.4 (3), p.149-154
Hauptverfasser: Li, Gen, Zhou, Zhongcheng, Du, Peng, Yu, Meixing, Li, Ning, Xiong, Xinxin, Huang, Hong, Liu, Zhihai, Dai, Qinjin, Zhu, Jie, Guo, Chengbin, Wu, Shanyun, Baptista-Hon, Daniel T, Miao, Man, Ming, Lam Wai, Wu, Yong, Zeng, Fanxin, Zhang, Charlotte L, Zhang, Edward D, Song, Haifeng, Liu, Jianghai, Lau, Johnson Yiu-Nam, Xiang, Andy P, Zhang, Kang
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract To assess the impact of the key non-synonymous amino acid substitutions in the RBD of the spike protein of SARS-CoV-2 variant B.1.617.1 (dominant variant identified in the current India outbreak) on the infectivity and neutralization activities of the immune sera, L452R and E484Q (L452R-E484Q variant), pseudotyped virus was constructed (with the D614G background). The impact on binding with the neutralizing antibodies was also assessed with an ELISA assay. Pseudotyped virus carrying a L452R-E484Q variant showed a comparable infectivity compared with D614G. However, there was a significant reduction in the neutralization activity of the immune sera from non-human primates vaccinated with a recombinant receptor binding domain (RBD) protein, convalescent patients, and healthy vaccinees vaccinated with an mRNA vaccine. In addition, there was a reduction in binding of L452R-E484Q-D614G protein to the antibodies of the immune sera from vaccinated non-human primates. These results highlight the interplay between infectivity and other biologic factors involved in the natural evolution of SARS-CoV-2. Reduced neutralization activities against the L452R-E484Q variant will have an impact on health authority planning and implications for the vaccination strategy/new vaccine development.
ISSN:2096-5303
2516-1571
2516-1571
DOI:10.1093/pcmedi/pbab016